| 产品描述: | Selpercatinib (LOXO-292, ARRY-192)是一种有效、特异的RET (c-RET)抑制剂,对WT RET (c-RET), RET (c-RET) (V804M), RET (c-RET) (V804L), RET (c-RET) (A883F), RET (c-RET) (M918T)和RET (c-RET) (S891A)的IC50值分别为1 nM、2 nM、2 nmM、4 nM、2 nM和2 nM |
| 靶点: |
RET wt(Cell-free assay):1 nM; RET V804M(Cell-free assay):2 nM; RET V804L(Cell-free assay):2 nM; RET M918T(Cell-free assay):2 nM; RET S891A(Cell-free assay):2 nM; RET A883F:4 nM;c-RET |
| 体外研究: |
Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor. |
| 体内研究: |
Selpercatinib (LOXO-292; 10 mg/kg; i.g.; for 0-2 h) has good pharmacokinetics after oral gavage in FVB/NRj mice. Pharmacokinetic Parameters of Selpercatinib in FVB/NRj mice. |
| 细胞实验: |
Cell lines: NB1 cells Concentrations: 1 μM Incubation Time: 2 h Method: Cells were pre-treated with LOXO292 (1 µM) for 2 h before stimulation with ALKAL2 or GDNF |
| 动物实验: |
Animal Models: Female nu/nu BALB/c mice Dosages: 3 mg/kg Administration: o.g. |
| 参考文献: |
1. B. Brandhuber, et al. Array BioPharma, Drug Discovery. ENA-0490/Poster No.441. 2. Siaw JT, et al. Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells. Cancers (Basel). 2021 Apr 15;13(8):1909. 3. Solomon BJ, et al. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol. 2020 Apr;15(4):541-549. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.903 ml |
9.513 ml |
19.026 ml |
| 5 mM |
0.381 ml |
1.903 ml |
3.805 ml |
| 10 mM |
0.19 ml |
0.951 ml |
1.903 ml |
| 50 mM |
0.038 ml |
0.19 ml |
0.381 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |